REGN
Price
$618.95
Change
+$16.03 (+2.66%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
64.89B
56 days until earnings call
Intraday BUY SELL Signals
SVRA
Price
$5.26
Change
+$0.01 (+0.19%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
1.08B
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REGN vs SVRA

Header iconREGN vs SVRA Comparison
Open Charts REGN vs SVRABanner chart's image
REGN vs SVRA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
REGN vs. SVRA commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Hold and SVRA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2026
Stock price -- (REGN: $618.95 vs. SVRA: $5.26)
Brand notoriety: REGN: Notable vs. SVRA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 108% vs. SVRA: 135%
Market capitalization -- REGN: $64.89B vs. SVRA: $1.08B
REGN [@Biotechnology] is valued at $64.89B. SVRA’s [@Biotechnology] market capitalization is $1.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.72B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 1 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • REGN’s FA Score: 1 green, 4 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, REGN is a better buy in the long-term than SVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 4 TA indicator(s) are bullish while SVRA’s TA Score has 4 bullish TA indicator(s).

  • REGN’s TA Score: 4 bullish, 4 bearish.
  • SVRA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both REGN and SVRA are a good buy in the short-term.

Price Growth

REGN (@Biotechnology) experienced а -1.40% price change this week, while SVRA (@Biotechnology) price change was +0.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.85%. For the same industry, the average monthly price growth was -4.25%, and the average quarterly price growth was +0.68%.

Reported Earning Dates

REGN is expected to report earnings on Jul 30, 2026.

SVRA is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-3.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($64.9B) has a higher market cap than SVRA($1.08B). SVRA YTD gains are higher at: -12.769 vs. REGN (-19.595). REGN has higher annual earnings (EBITDA): 5.75B vs. SVRA (-120.38M). SVRA has less debt than REGN: SVRA (29.8M) vs REGN (2.71B). REGN has higher revenues than SVRA: REGN (14.9B) vs SVRA (0).
REGNSVRAREGN / SVRA
Capitalization64.9B1.08B6,020%
EBITDA5.75B-120.38M-4,773%
Gain YTD-19.595-12.769153%
P/E Ratio15.11N/A-
Revenue14.9B0-
Total CashN/A124M-
Total Debt2.71B29.8M9,081%
FUNDAMENTALS RATINGS
REGN vs SVRA: Fundamental Ratings
REGN
SVRA
OUTLOOK RATING
1..100
5210
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
62
Fair valued
PROFIT vs RISK RATING
1..100
8749
SMR RATING
1..100
5999
PRICE GROWTH RATING
1..100
6345
P/E GROWTH RATING
1..100
36100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (2) in the Biotechnology industry is somewhat better than the same rating for SVRA (62). This means that REGN’s stock grew somewhat faster than SVRA’s over the last 12 months.

SVRA's Profit vs Risk Rating (49) in the Biotechnology industry is somewhat better than the same rating for REGN (87). This means that SVRA’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for SVRA (99). This means that REGN’s stock grew somewhat faster than SVRA’s over the last 12 months.

SVRA's Price Growth Rating (45) in the Biotechnology industry is in the same range as REGN (63). This means that SVRA’s stock grew similarly to REGN’s over the last 12 months.

REGN's P/E Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for SVRA (100). This means that REGN’s stock grew somewhat faster than SVRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REGNSVRA
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
61%
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
56%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
61%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 15 days ago
64%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
54%
Bearish Trend 13 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
REGN
Daily Signal:
Gain/Loss:
SVRA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
POSKX40.50N/A
N/A
PRIMECAP Odyssey Stock
RIDAX27.32N/A
N/A
American Funds Income Fund of Amer R1
SMFPX12.28N/A
N/A
Westwood Salient MLP & Engy Infras C
ENHNX11.12N/A
N/A
Cullen Enhanced Equity Income I
FCIRX18.33-0.11
-0.60%
NYLI PineStone International Equity Cl A

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with SMMT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then SMMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+2.66%
SMMT - REGN
42%
Loosely correlated
+1.41%
ARQT - REGN
38%
Loosely correlated
+2.72%
PCVX - REGN
33%
Poorly correlated
-1.01%
SVRA - REGN
32%
Poorly correlated
+0.19%
GMAB - REGN
32%
Poorly correlated
+0.10%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with RCKT. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
+0.19%
RCKT - SVRA
61%
Loosely correlated
+1.04%
NUVB - SVRA
41%
Loosely correlated
-3.67%
NRIX - SVRA
39%
Loosely correlated
-5.47%
KYTX - SVRA
38%
Loosely correlated
-1.01%
SNDX - SVRA
37%
Loosely correlated
-0.30%
More